ARS Pharmaceuticals, Inc. SPRY
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) is a dermatology drug developer. Its lead program, ARS-2, is in Phase 2 for Chronic spontaneous urticaria (CSU) - acute flares. Its next catalyst on record is ARS-2: Interim Phase 2b data (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ARS-2 — Interim Phase 2b data (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| neffy (intranasal epinephrine) | Type I allergic reactions, including anaphylaxis | small molecule | Approved |
| ARS-2 | Chronic spontaneous urticaria (CSU) - acute flares | small molecule | Phase 2 |
Recent results and decisions
- May 15, 2026approval FDA approved removing the age criteria from the 1 mg neffy label in late March 2026, so all patients weighing 33 lbs or more can use it.
FDA approved removing the age criteria in late March 2026, so all children and adults who weigh 33 lbs or more can utilize neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.